Search Results
Benefits of second generation TKIs for CML in the frontline
CML: Considering Second-Generation TKIs
Should All Newly Diagnosed CP-CML Patients Start with a 2nd-generation TKI as Frontline Therapy?
The current standard of care in CML and insights into the use of first- and second-generation TKIs
Bosutinib: a new, safer TKI for frontline CML
Dr. Pamela Crilley on Imatinib and Second Generation TKIs
Four Approved Frontline Treatments Benefit Patients with Chronic Myeloid Leukemia
UPFRONT 2ND GENERATION TKI FOR NEWLY DIAGNOSED CHRONIC PHASE CML? QIAN JIANG
Comparing Frontline Therapies for the Treatment of Chronic Myeloid Leukemia
Asciminib versus other TKIs in the frontline treatment of CML: the ASC4FIRST study
The NILSt and D-STOP Trials in CML
Upfront Treatment in Chronic Myeloid Leukemia (CML)
